Topical botulinum toxin

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 3, 2010, Pages

  Collins, Ashley ^a   Nasir, Adnan ^b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONTA CREAM; BOTULINUM TOXIN A; RT001; TOPICAL TOXIN-A CREAM; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL COMPOSITION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG UTILIZATION; DRY EYE; DRY SKIN; ECZEMA; ERYTHEMA; EYE BURNING; EYE IRRITATION; FOLLICULITIS; HUMAN; HYPERHIDROSIS; LOW DRUG DOSE; MUSCLE CONTRACTION; NERVE BLOCK; NONHUMAN; OSTEOLYSIS; PAIN; PARALYSIS; PRACTICE GUIDELINE; PRURITUS; SENSORY NERVE; SOCIAL ASPECT; WRINKLE;

EID: 77954250808     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5:274-279.
2. Hallet M. One man's poison-Clinical applications of botulinum toxin. N Engl J Med. 1999; 341:118-120.
3. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-1768.
4. Chajchir I, Modi P, Chajchir A. Novel topical BoNTA (CosmeTox, Toxin Type A) cream used to treat hyperfunctional wrinkles of the face, mouth, and neck. Aesthetic Plast Surg. 2008;32:715-722.
5. Said SZ, Meshkinpour A, Carruthers A, Carruthers J. Botulinum toxin A. Its expanding role in dermatology and esthetics. Am J Clin Dermatol. 2003;4(9):609-616.
6. Yamauchi PS, Lowe NJ. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhydrosis. Clin Dermatol. 2004;22(1):34-39.
7. Allergan Inc. BOTOX (Botulinum toxin type A) mechanism of action. www.allergan.com/assets/ pdf/botox_mechanism_of_action.pdf. Accessed on February 24, 2010.
8. Dressler D, Saberi FA, Barbosa FR. Botulinum toxin. Mechanisms of action. Arq Neuropsiquiatr. 2005;63(1):180-185.
9. Grimston SK, Silva MJ, Civitelli R. Bone loss after temporarily induced muscle paralysis by Botox is not fully recovered after 12 weeks. Ann N Y Acad Sci. 2007;1116: 444-460.
10. Flynn TC. Update on botulinum toxin. Semin Cutan Med Surg. 2006;25:115-121.
11. Modi P. Technical overview of topical botulinum toxin. http://www.transdermalcorp.com/. Accessed on February 24, 2010.
12. Revance Therapeutics. Topical botulinum toxin type A for the treatment of lateral canthal lines. http://www.revance. com/385-rt0010lcl?side. Accessed on February 24, 2010.
13. Singh GC, Hankins MC, Dulku A, Kelly MBH. Psychosocial aspects of Botox in aesthetic surgery. Aesth Plast Surg. 2006;30:71-76.
14. Melville NA. Botulinum toxin in topical form draws interest. Dermatol Times. 2008. http://www.modernmedicine.com/ modernmedicine/News/Botulinum-toxin-in-topical-form-draws-interest/ArticleStandard/Article/detail/500758. Accessed on March 1, 2010.
15. Nasir A. Dermatologic toxicity of nanoengineered materials. Arch Derm. 2008:144:253-254.
16. Atamoros FP. Botulinum toxin type A for the treatment of moderate to severe lateral canthal lines: preliminary safety and efficacy results of a blinded, randomized, placebo controlled trial. Poster presented at: The American Academy of Dermatology's 2009 Summer Academy; July 29-August 2, 2009; Boston, Massachusetts.
17. Glogau R. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg. 2007;33:S76-S80.